Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages

Biochem Pharmacol. 1995 Nov 27;50(11):1753-9. doi: 10.1016/0006-2952(95)02030-6.

Abstract

Gold compounds are widely used in the treatment of rheumatoid arthritis, but their mechanisms of action remain unclear. We demonstrate here that auranofin (AF) (0.1-3 microM), but neither the hydrophilic gold compounds aurothiomalate (ATM) and aurothioglucose nor methotrexate or D-penicillamine, inhibits the induction of interleukin 1 beta and tumor necrosis factor (TNF) alpha mRNA and protein by either zymosan, lipopolysaccharide (LPS), or various bacteria in mouse macrophages. The auranofin-mediated inhibition of the induction of TNF-alpha mRNA was stronger than that of interleukin (IL) 1 beta mRNA. AF, but not the other drugs, also inhibited zymosan-induced mobilization of arachidonate. The fact that AF inhibited the induction of mRNA for both these proinflammatory cytokines, irrespective of which stimulus was used, may indicate that it affects some common signal transduction step vital to their induction.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antirheumatic Agents / pharmacology*
  • Auranofin / pharmacology*
  • Aurothioglucose / pharmacology
  • Base Sequence
  • Female
  • Gold Sodium Thiomalate / pharmacology
  • Interleukin-1 / biosynthesis*
  • Lipopolysaccharides / antagonists & inhibitors
  • Macrophages, Peritoneal / drug effects*
  • Macrophages, Peritoneal / metabolism
  • Mice
  • Molecular Sequence Data
  • Phosphorylation / drug effects
  • RNA, Messenger / biosynthesis*
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Zymosan / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Interleukin-1
  • Lipopolysaccharides
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Gold Sodium Thiomalate
  • Aurothioglucose
  • Auranofin
  • Zymosan